# E136: Secukinumab in PMR (REPLENISH)

Page: https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish
Text version: https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish.md
Podcast: [The Evidence Based Rheumatology Podcast](https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175)
Published: 2026-06-15T14:12:00+00:00
Episode link: https://msputman.podbean.com/e/e136-secukinumab-in-pmr-replenish/
Audio file: https://mcdn.podbean.com/mf/web/k8vibwq2e8x52wsh/e136.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e136-secukinumab-in-pmr-replenish
Duration seconds: 819

## Resource

Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with. Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e136-secukinumab-in-pmr-replenish/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.